[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569276":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":41,"responsibleParty":94,"collaborators":26,"id":96,"slug":26,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":97,"sex":103,"minAge":104,"maxAge":26,"enrollmentInfo":105,"targetDuration":26,"studyType":108,"phases":109,"briefSummary":111,"conditions":112,"keywords":116,"overallStatus":44,"whyStopped":26,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},{"fullName":5,"class":6},"Odense University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent","EXPERIMENTAL","Percutaneous coronary interventin with Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent",[13],"Device: Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s)",{"label":15,"type":16,"description":17,"interventionNames":18},"Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent)","ACTIVE_COMPARATOR","Percutaneous coronary intervention with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent)",[19],"Device: PCI with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s)","Percutaneous coronary intervention with Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s)",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"PCI with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))","Percutaneous coronary intervention with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))",[15],[32],{"name":33,"affiliation":5,"role":34},"Lisette O Jensen","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Lisette O Jensen, MD","CONTACT","+4565412690","lisette.okkels.jensen@rsyd.dk",[42,63,80],{"facility":43,"status":44,"city":45,"state":26,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Aalborg University Hospital","RECRUITING","Aalborg","9000","Denmark","DK",{"type":50,"coordinates":51},"Point",[52,53],9.9187,57.048,{"lat":53,"lon":52},[56,60,61],{"name":57,"role":38,"phone":58,"phoneExt":26,"email":59},"Ashkan Eftekhari, MD","+4597660000","asef@rn.dk",{"name":57,"role":38,"phone":26,"phoneExt":26,"email":26},{"name":62,"role":38,"phone":26,"phoneExt":26,"email":26},"Phillip Freeman, MD",{"facility":64,"status":44,"city":65,"state":26,"zip":66,"country":47,"countryCode":48,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Aarhus University Hospital","Aarhus","8200",{"type":50,"coordinates":68},[69,70],10.21076,56.15674,{"lat":70,"lon":69},[73,77,78],{"name":74,"role":38,"phone":75,"phoneExt":26,"email":76},"Evald H Christiansen, MD","+4578450000","evald.christiansen@rm.dk",{"name":74,"role":38,"phone":26,"phoneExt":26,"email":26},{"name":79,"role":38,"phone":26,"phoneExt":26,"email":26},"Lars Jakobsen, MD",{"facility":5,"status":44,"city":81,"state":26,"zip":82,"country":47,"countryCode":48,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"Odense","5000",{"type":50,"coordinates":84},[85,86],10.38831,55.39594,{"lat":86,"lon":85},[89,91,92],{"name":37,"role":38,"phone":90,"phoneExt":26,"email":40},"+4565412620",{"name":37,"role":38,"phone":26,"phoneExt":26,"email":26},{"name":93,"role":38,"phone":26,"phoneExt":26,"email":26},"Jens F Lassen, MD",{"type":95,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100569276",false,"NCT06692140","Comparison of an Ultra-low Strut Thickness Everolimus-eluting Biodegradable Polymer Stent Versus Durable Polymer Everolimus-eluting Stents in Patients Treated with Percutaneous Coronary Intervention","Randomized Comparison of an Ultra-low Strut Thickness Everolimus-eluting Biodegradable Polymer Stent Versus Durable Polymer Everolimus-eluting Stents in Patients Treated with Percutaneous Coronary Intervention in an All Comer Population (The SORT OUT XII Trial)","SORT OUT XII","Inclusion Criteria:\n\n* All patients aged ≥18 years who are eligible for treatment with one or several drug-eluting coronary stents\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Not able to consent to study participating (eg. intubated patients)\n* Unstable circuit or in cardiogenic shock and therefore not able to understand the information and purpose of the study\n* Do not speak Danish\n* Already included in the SORT OUT XII study\n* Life expectancy \\\u003C1 year\n* Allergic to study related treatment","ALL","18 Years",{"count":106,"type":107},3150,"ESTIMATED","INTERVENTIONAL",[110],"NA","The objective of this randomized study is to compare the safety and efficacy of the ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent to the everolimus-eluting family stents (durable polymer everolimus-eluting Xience or Promus stents) in a population-based setting with coronary artery stenosis treated with percutaneous coronary intervention",[113,114,115],"Ischemia, Myocardial","Coronary Artery Disease","Percutaneous Coronary Intervention (PCI)",[117,118],"Drug-eluting stent","outcome","2024-12-04",{"date":121,"type":122},"2024-12-09","ACTUAL",{"date":124,"type":122},"2024-11-16",{"date":126,"type":107},"2032-07-01",{"name":5,"class":6},3]